Jonathan Levine Wasserman, Articles F

2008;11:32-43. We, Yahoo, are part of the Yahoo family of brands. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. Find out more about how we use your personal data in our privacy policy and cookie policy. Bayer acquired elinzanetant as part of its takeover of UK biotech KaNDy Therapeutics in 2020, while Astellas acquired fezolinetant as part of its 2017 takeover of Ogeda. News | Astellas Pharma Inc. For more information, please see the press release "U.S. FDA Accepts Astellas' New Drug Application for Fezolinetant" issued on August 18, 2022. 8Fraser GL, Lederman S, Waldbaum A, Kroll R, Santoro N, Lee M, et al. Fezolinetant Shows Positive Response in Vasomotor Symptoms Associated Endocrinology. For more information, please see the press release "U.S. FDA Accepts Astellas' New Drug Application for Fezolinetant" issued on August 18, 2022. "I am excited by the potential of a new nonhormonal treatment option for women experiencing moderate to severe VMS associated with menopause.". Fezolinetant is an investigational oral, nonhormonal therapy in clinical development for the treatment of moderate to severe VMS due to menopause. 2006;96:1226-1235. "The fezolinetant NDA submission to the U.S. FDA is an important step in our efforts to bring to patients a first-in-class, nonhormonal treatment option to reduce the frequency and severity of moderate to severe VMS associated with menopause.". Fezolinetant works by blocking neurokinin B (NKB) binding on the kisspeptin/neurokinin B/dynorphin (KNDy) neuron to modulate neuronal activity in the thermoregulatory center of the brain (the hypothalamus) to reduce the frequency and severity of moderate to severe VMS due to menopause.